Inhibition of HIV-1 replication by targeting the Rev protein.
Human immunodeficiency virus type 1 (HIV-1) encodes two regulatory proteins, Tat and Rev. The Rev protein facilitates the transport of unspliced and singly-spliced RNA to the cytoplasm in infected host cells by binding to target RNA (Rev response element: RRE). A variety of approaches targeting Rev function, including gene therapy, have been developed that inhibit HIV-1 replication in cells cultured in vitro. This minireview summarizes the recent developments as well as our application of the Rev-binding element-based decoy approach using RNA-DNA chimera oligonucleotide modeling.
Nakaya
T
T
Institute of Immunological Science, Faculty of Pharmaceutical Science, Hokkaido University, Sapporo, Japan.
Iwai
S
S
Fujinaga
K
K
Otsuka
E
E
Ikuta
K
K
D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D001483:Base Sequence; D002678:Chimera; D004279:DNA, Viral / Q000378:metabolism; D015195:Drug Design; D015694:Gene Products, rev / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000494:pharmacology*; D012326:RNA Splicing; D012367:RNA, Viral / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects*; D054321:rev Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D004279:DNA, Viral; D015694:Gene Products, rev; D009838:Oligodeoxyribonucleotides; D012367:RNA, Viral; D054321:rev Gene Products, Human Immunodeficiency Virus